Results 181 to 190 of about 8,546 (246)

Bumetanide, a Diuretic That Can Help Children with Autism Spectrum Disorder.

CNS and Neurological Disorders - Drug Targets, 2023
BACKGROUND Autism Spectrum Disorder (ASD) is a common child neurodevelopmental disorder, whose pathogenesis is not completely understood. Until now, there is no proven treatment for the core symptoms of ASD.
E. Shaker, Osama El Agami, Abeer Salamah
semanticscholar   +1 more source

Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide impurity formation and its inhibition in bumetanide tablets.

Journal of Pharmacy and Science, 2023
Nitrosamine compounds are classified as potential human carcinogens, the origin of these impurities in the drugs can be broadly classified in two categories, nitrosamine impurity found in drug products that are not associated with the Active ...
D. Shakleya, B. Asmelash, A. Alayoubi, Nicolas Abrigo, Adil Mohammad, Jiang Wang, Jinhui Zhang, Jingyue Yang, Tim Marzan, David Li, Maha Shaklah, Fahd M. Alsharif, Saaniya Desai, P. Faustino, Muhammad Ashraf, Thomas O'Connor, M. Vera, A. Raw, V. Sayeed, D. Keire   +19 more
semanticscholar   +1 more source

Targeting AgrA quorum sensing regulator by bumetanide attenuates virulence in Staphylococcus aureus - A drug repurposing approach.

Life Science, 2021
AIMS The present study aims to target the quorum sensing (QS) accessory gene regulator A (AgrA) of Staphylococcus aureus to curtail bacterial virulence through drug repurposing approach.
Balamurugan Palaniappan, A. P. Solomon, David Raj C   +2 more
semanticscholar   +1 more source

A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia

Epilepsia, 2021
Bumetanide was suggested as an adjunct to phenobarbital for suppression of neonatal seizures. This suggestion was based on the idea that bumetanide, by reducing intraneuronal chloride accumulation through inhibition of the Na‐K‐2Cl cotransporter NKCC1 ...
Marie Johne, Christopher Käufer, Kerstin Römermann, Björn Gailus, Birthe Gericke, W. Löscher   +5 more
semanticscholar   +1 more source

Bumetanide and furosemide

Clinical Pharmacology and Therapeutics, 1983
We assessed the response to and handling of furosemide and bumetanide in 30 experiments with the former and 46 with the latter in normal subjects. Oral doses of furosemide (20, 40, and 80 mg) were used, and subjects received oral doses of 0.5, 1, and 2 mg bumetanide and intravenous doses of 0.5 and 1 mg bumetanide.
D C, Brater, P, Chennavasin, B, Day, A, Burdette, S, Anderson   +4 more
openaire   +2 more sources

Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice.

Neuropharmacology, 2021
The sodium-potassium-chloride (Na-K-Cl) cotransporter NKCC1 is found in the plasma membrane of a wide variety of cell types, including neurons, glia and endothelial cells in the brain. Increased expression of neuronal NKCC1 has been implicated in several
Philip Hampel, Kerstin Römermann, Björn Gailus, Marie Johne, Birthe Gericke, E. Kaczmarek, W. Löscher   +6 more
semanticscholar   +1 more source

Pharmacology of Bumetanide

The Journal of Clinical Pharmacology, 1981
Abstract:The diuretic action of bumetanide was compared with that of furosemide following oral and intravenous administration of equipotent doses in the rat, mouse, cat, rabbit, and dog. The onset of the bumetanide‐induced diuresis was rapid and lasted 4 to 6 hours.
openaire   +2 more sources

The NKCC1 Inhibitor Bumetanide Restores Cortical Feedforward Inhibition and Lessens Sensory Hypersensitivity in Early Postnatal Fragile X Mice

Biological Psychiatry
BACKGROUND: Exaggerated responses to sensory stimuli, a hallmark of fragile X syndrome, contribute to anxiety and learning challenges. Sensory hypersensitivity is recapitulated in the Fmr1 knockout (KO) mouse model of fragile X syndrome.
Nazim Kourdougli, Toshihiro Nomura, Michelle W. Wu, A. Heuvelmans, Zoë Dobler, A. Contractor, C. Portera-Cailliau   +6 more
semanticscholar   +1 more source

Metabolism of Bumetanide

The Journal of Clinical Pharmacology, 1981
Abstract: The metabolism of bumetanide is reviewed, with emphasis on the relationship between metabolism and diuretic activity. Substantial evidence has been obtained for the thesis that diuretic activity is dependent on the amount of bumetanide which reaches the renal tubule.
openaire   +2 more sources

The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain.

Epilepsy & Behavior, 2020
Because of its potent inhibitory effect on the Na+-K+-2Cl- symporter isotype 1 (NKCC1) in brain neurons, bumetanide has been tested with varying results for treatment of seizures that potentially evolve as a consequence of abnormal NKCC1 activity ...
Philip Hampel, Kerstin Römermann, M. Gramer, W. Löscher   +3 more
semanticscholar   +1 more source